Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Federico, Hinestrosa"'
Publikováno v:
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-11 (2021)
Abstract Background Dolutegravir (DTG) monotherapy results in virologic failure and the development of DTG resistance. Here, we evaluated virologic outcomes of patients switched to DTG functional mono- or dual therapy with a non-cytosine nucleoside a
Externí odkaz:
https://doaj.org/article/99325f8b0a7245c5bb8e6acf1a28eea3
Publikováno v:
Journal of Virus Eradication, Vol 6, Iss 4, Pp 100021- (2020)
Background: Multi-tablet regimens (MTRs) are associated with increased adverse events and non-adherence. Single tablet regimens (STRs) plus boosted protease inhibitors (PIs) are a simplification option for MTR-treated patients; however, data is neede
Externí odkaz:
https://doaj.org/article/57837412363f4d1d970f57687b6c0f42
Autor:
Gregory D Huhn, Moti Ramgopal, Mamta K Jain, Federico Hinestrosa, David M Asmuth, Jihad Slim, Deborah Goldstein, Shauna Applin, Julie H Ryu, Shuping Jiang, Stephanie Cox, Moupali Das, Thai Nguyen-Cleary, David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard H Haubrich
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0224875 (2020)
IntroductionGuidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate th
Externí odkaz:
https://doaj.org/article/17f99115a1574511a445b8925d582138
Publikováno v:
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-11 (2021)
AIDS Research and Therapy
AIDS Research and Therapy
BackgroundDolutegravir (DTG) monotherapy results in virologic failure and the development of DTG resistance. Here, we evaluated virologic outcomes of patients switched to DTG functional mono- or dual therapy with a non-cytosine nucleoside analog (NA)
Autor:
Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen, Kiran Patel, Federico Hinestrosa, Edwin DeJesus
Publikováno v:
Antiviral Therapy. 28:135965352311637
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INST
Autor:
Patrick Horne, Anquenette P Sloan, K. Rajender Reddy, Mandana Khalili, Donna M. Evon, Juhi S Moon, Mark S. Sulkowski, Larry Michael, Scott Kixmiller, Michael W. Fried, David R. Nelson, Mitchell L. Shiffman, Meichen Dong, Monika Vainorius, Jama M. Darling, Jodi B Segal, Dawn Fishbein, Joy Peter, Paul W. Stewart, Summer Wadsworth, Kenneth E. Sherman, Brian L. Pearlman, Andrew J. Muir, Giuseppe Morelli, Federico Hinestrosa, Adrian M. Di Bisceglie, Prioritize Study Team, Anna S. Lok
Publikováno v:
Hepatology (Baltimore, Md.). 74(6)
Background and aims Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. Approach and results We conducte
Publikováno v:
Medicine
Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated potent efficacy and favorable safety in older PLWH; however, real-w
Autor:
Charlotte-Paige M Rolle, Jamie Castano, Vu Nguyen, Kiran Patel, Federico Hinestrosa, Edwin DeJesus
Publikováno v:
Open Forum Infectious Diseases
Background Cohort studies suggest higher rates of discontinuations (DCs) and adverse events (AEs) with integrase inhibitors (INSTIs) than is reported in clinical trials. Here, we assess DC of different INSTIs in combination with one of two tenofovir
Background Dolutegravir (DTG) monotherapy results in unacceptable virologic failure rates and the development of DTG resistance. Here, we evaluated virologic outcomes of patients switched to DTG functional monotherapy, or functional dual therapy with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb8c2b4059208fa0e690b29776aa10c2
https://doi.org/10.21203/rs.3.rs-74793/v1
https://doi.org/10.21203/rs.3.rs-74793/v1
Publikováno v:
International journal of STDAIDS. 31(10)
Darunavir (DRV) is approved for once-daily use in patients with no DRV resistance-associated mutations (RAMs) and twice-daily use in those with DRV RAMs. Several studies suggest that once-daily DRV retains efficacy in the setting of 1–2 DRV RAMs wh